西藏药业：新活素纳入新版医保目录并“转常规”，惠及更多心衰患者

Core Viewpoint - The announcement regarding the inclusion of the drug Xinhuasuan in the national medical insurance drug list indicates a significant shift for the company, as it transitions from a negotiable agreement drug to a stable inclusion in the regular catalog, enhancing long-term revenue predictability [1][2]. Group 1: Product and Market Impact - Xinhuasuan, developed by the company's subsidiary Chengdu Nuodikan Biopharmaceutical Co., Ltd., is a new biological product for treating acute heart failure, which improves patient symptoms and reduces hospitalization costs [1]. - The sales volume for Xinhuasuan is projected to reach 7.0083 million units in 2024, generating revenue of 2.433 billion yuan, with 4.1672 million units and 1.456 billion yuan expected in the first half of 2025 [2]. - The drug's penetration in the large heart failure market remains low, indicating substantial growth potential following its transition to the regular catalog, which will stabilize pricing and support long-term performance growth [2]. Group 2: Additional Developments - The company’s associate, Chentai Pharmaceutical, has also seen its drug Zorifertinib included in the medical insurance catalog, with a negotiation agreement effective from January 1, 2026, to December 31, 2027 [2]. - Zorifertinib is recognized as the first drug targeting advanced non-small cell lung cancer with central nervous system metastasis, which is expected to accelerate its commercial value realization after being included in the insurance catalog [2].